71.05
-0.42 (-0.59%)
Previous Close | 71.47 |
Open | 71.47 |
Volume | 127,581 |
Avg. Volume (3M) | 1,794,205 |
Market Cap | 2,391,545,088 |
Price / Earnings (TTM) | 66.40 |
Price / Earnings (Forward) | 56.50 |
Price / Sales | 6.81 |
Price / Book | 12.63 |
52 Weeks Range | |
Earnings Date | 28 Apr 2025 - 2 May 2025 |
Profit Margin | 8.03% |
Operating Margin (TTM) | 7.11% |
Diluted EPS (TTM) | 1.07 |
Quarterly Revenue Growth (YOY) | 49.80% |
Quarterly Earnings Growth (YOY) | 70.10% |
Total Debt/Equity (MRQ) | 226.72% |
Current Ratio (MRQ) | 8.30 |
Operating Cash Flow (TTM) | 48.80 M |
Levered Free Cash Flow (TTM) | -102.77 M |
Return on Assets (TTM) | 3.10% |
Return on Equity (TTM) | 19.39% |
Market Trend
Short Term | Medium Term | ||
Industry | Medical Devices (US) | Bearish | Mixed |
Medical Devices (Global) | Bearish | Mixed | |
Stock | TransMedics Group, Inc. | Bullish | Bullish |
AIStockmoo Score
Analyst Consensus | 3.0 |
Insider Activity | NA |
Price Volatility | 4.5 |
Technical Moving Averages | 1.0 |
Technical Oscillators | 0.0 |
Average | 2.13 |
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. |
|
Sector | Healthcare |
Industry | Medical Devices |
Investment Style | Small Growth |
% Held by Insiders | 3.48% |
% Held by Institutions | 115.50% |
52 Weeks Range | ||
Price Target Range | ||
High | 130.00 (Oppenheimer, 82.98%) | Buy |
Median | 125.00 (75.95%) | |
Low | 104.00 (Canaccord Genuity, 46.39%) | Buy |
Average | 119.67 (68.44%) | |
Total | 3 Buy | |
Avg. Price @ Call | 22.55 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Oppenheimer | 09 May 2025 | 130.00 (82.98%) | Buy | 0.000 |
Piper Sandler | 09 May 2025 | 125.00 (75.94%) | Buy | 0.000 |
29 Apr 2025 | 105.00 (47.79%) | Buy | 92.43 | |
Canaccord Genuity | 11 Mar 2025 | 104.00 (46.39%) | Buy | 67.65 |
No data within this time range.
Date | Type | Details |
---|---|---|
20 May 2025 | Announcement | TransMedics to Present at Upcoming June Investor Conferences |
08 May 2025 | Announcement | TransMedics Reports First Quarter 2025 Financial Results |
24 Apr 2025 | Announcement | TransMedics to Report First Quarter 2025 Financial Results on May 8, 2025 |
02 Apr 2025 | Announcement | TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
24 Mar 2025 | Announcement | SHAREHOLDER DEADLINE: TransMedics Group (TMDX) Investors Are Reminded of Deadline in Securities Action |
17 Mar 2025 | Announcement | ATTENTION TRANSMEDICS GROUP (TMDX) SHAREHOLDERS: Securities Fraud Lawsuit Filed Against TransMedics Group (TMDX) |
27 Feb 2025 | Announcement | TransMedics Reports Fourth Quarter and Full Year 2024 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |